⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

February 14, 2022Alzheimer s Research & TherapyOpen Access

Combination of gut microbiota and plasma amyloid-β as a potential index for identifying preclinical Alzheimer’s disease: a cross-sectional analysis from the SILCODE study

View Full Paper

Ask AI

Bookmark

Share

Abstract

This study has been registered in ClinicalTrials.gov (NCT03370744, https://www.clinicaltrials.gov ) in November 15, 2017.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Sheng et al. (2022) studied this question.

synapsesocial.com/papers/69de91bf6bae133e7de93e33 https://doi.org/10.1186/s13195-022-00977-x

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Short-Term Delayed Recall of Auditory Verbal Learning Test Is Equivalent to Long-Term Delayed Recall for Identifying Amnestic Mild Cognitive ImpairmentOriginal Research · 2012 · 258 citations
2Improved Power for Characterizing Longitudinal Amyloid-β PET Changes and Evaluating Amyloid-Modifying Treatments with a Cerebral White Matter Reference RegionCohort Study · 2015 · 159 citations
3The cost of Alzheimer's disease in China and re‐estimation of costs worldwideCross-Sectional Study · 2018 · 749 citations
4Sino Longitudinal Study on Cognitive Decline (SILCODE): protocol for a Chinese longitudinal observational study to develop risk prediction models of conversion to mild cognitive impairment in individuals with subjective cognitive declineCohort Study · 2019 · 118 citations
5Interactions Between the Microbiota and the Immune SystemReview · 2012 · 4,288 citations